ESR1 and ovarian carcinoma: In this study about 57 Tunisian patients with ovarian carcinoma, biomarkers expression was evaluated by immunohistochemistry and was observed in 42 cases (73.7%) for p53, 27 cases (47.4%) for Bcl-2, 20 cases (35.1%) for ER and 19 cases (33.3 %) for PR.